What's new? Log in Free sign up

GSK (GSK)

Company Profile

Company profile

Ticker

GSK, GLAXF

Exchange

Website

CEO

Ms. Emma Natasha Walmsley

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

GLAXOSMITHKLINE PLC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

GSK stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Director/pdmr Shareholding

Block Listing Application

Headline Results from Phase III First Trial

Jemperli Receives Us Fda Breakthrough Designation

Ema Grants Prime Designation for GSK 227

Jemperli Receives Positive CHMP Opinion

Director/pdmr Shareholding

Overall Survival Data Presented for Blenrep

Blenrep Combination China Filing Acceptance

Nucala Copd Submission Accepted by Us Fda

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

23andMe Holding Co.

GSK / GSK ownership change

Wave Life Sciences Ltd.

Annual report of employee stock purchases

Annual report of employee stock purchases

23andMe Holding Co.

Wave Life Sciences Ltd.

Financial summary

Financial statements Chart GSK financial data

Quarter (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from GSK earnings reports.

Institutional ownership, Q3 2024

GSK institutional ownership history Ownership history

14.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	869	858	+1.3%
Opened positions	90	79	+13.9%
Closed positions	79	104	-24.0%
Increased positions	293	296	-1.0%
Reduced positions	305	292	+4.5%

13F shares	Current	Prev Q	Change
Total value	10.56 tn	10.07 tn	+4.9%
Total shares	299.49 mm	306.50 mm	-2.3%
Total puts	1.86 mm	1.77 mm	+5.2%
Total calls	3.38 mm	3.28 mm	+3.2%
Total put/call ratio	0.6	0.5	+1.9%

Largest owners	Shares	Value	Change
Dodge & Cox	68.09 mm	$2.78 tn	-0.4%
FMR	29.01 mm	$1.19 tn	+8.3%
JTC Employer Solutions Trusteee	20.48 mm	$837.36 mm	-1.9%
Fisher Asset Management	18.58 mm	$759.42 bn	+4.9%
Primecap Management	14.85 mm	$607.22 bn	+2.4%
MS Morgan Stanley	7.95 mm	$325.15 bn	-21.3%
T. Rowe Price	7.53 mm	$307.90 mm	-26.4%
GS The Goldman Sachs Group, Inc.	7.37 mm	$301.30 bn	+77.3%
RY Royal Bank of Canada	7.17 mm	$293.23 bn	+1.9%
STT State Street	6.78 mm	$279.72 bn	-0.4%

Largest transactions	Shares	Bought/sold	Change
Holocene Advisors	65.30 k	-5.62 mm	-98.9%
Mondrian Investment Partners	0.00	-4.90 mm	EXIT
GS The Goldman Sachs Group, Inc.	7.37 mm	+3.21 mm	+77.3%
T. Rowe Price	7.53 mm	-2.70 mm	-26.4%
Acadian Asset Management	4.07 mm	+2.36 mm	+137.8%
FMR	29.01 mm	+2.22 mm	+8.3%
MS Morgan Stanley	7.95 mm	-2.15 mm	-21.3%
BLK BlackRock	0.00	-1.68 mm	EXIT
BLK BlackRock	1.59 mm	+1.59 mm	NEW
Millennium Management	1.46 mm	+1.38 mm	+1849.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

GSK insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Sep 24	GSK	Ordinary Shares	Buy	Acquire P	Yes	No	8	2,791,930	22.34 mm	16,775,691
7 Dec 23	GSK	Ordinary Shares	Buy	Acquire P	Yes	No	5	3,300,000	16.50 mm	13,983,761

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.

CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts

https://www.gov.ca.gov/2024/12/18/governor-newsom-takes-proactive-action-to-strengthen-robust-state-response-to-bird-flu/#:~:text=What%20you%20need%20to%20know,ongoing%20cross%2Dagency%20response%20efforts

CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana

https://www.cdc.gov/bird-flu/situation-summary/index.html

What's Going On Moderna Stock On Monday?

GSK Announces The U.S. FDA Has Granted Breakthrough Therapy Designation For Jemperli For The Treatment Of Patients With Locally Advanced Mismatch Repair Deficient/ Microsatellite Instability-High Rectal Cancer

Press releases

From Benzinga Pro

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

PALM BEACH, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - One of the most common malignancies in the world today is gastric cancer. The incidence rate is influenced by various factors,

Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse

DREAMM-7 trial shows sustained overall survival benefit for belantamab mafodotin combination versus daratumumab combination; benefit seen early and maintained through follow-up Data build on findings from DREAMM-7

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are

New Data for AREXVY, GSK's Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.